Alendronic acid - Osteoporosis
You are here : Home > Formulary Search > Alendronic acid - Osteoporosis
Status 1
- Tablets
ONCE WEEKLY tablets
ONCE DAILY tablets
Status 2
- Oral solution
Reserve for patients with swallowing difficulties.
Status 3
- Effervescent tablets
Reserve for patients who have tried alendronate and/or risedronate but are unable to swallow tablets (as opposed to patients with swallowing difficulties in whom the oral solution may be appropriate).
Documentation
PAD Profile
Other Indications
Below are listed other indications that Alendronic acid is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Osteoporosis.
Committee Recommendations (2)
The Surrey Heartlands Area Prescribing Committee (APC) approve the use of alendronic acid effervescent tablets (Binosto©) as a treatment option for postmenopausal osteoporosis.
Binosto will be assigned a GREEN (see narrative) traffic light status for this indication in patients that have already tried alendronate and/or risedronate tablets and are unable to swallow tablets (as opposed to those with swallowing difficulties).
The alendronate 70mg effervescent tablets are currently (Sep 2021) less costly than the equivalent dose in liquid formulation but considerably more costly than genrically prescribed 70mg tablets.
The PCN recommends Alendronate (Alendronic acid) 70mg/100ml Oral Solution as a treatment option for patients with post-menopausal osteoporosis who are:
- unable to swallow tablets; AND
- can meet the practical requirements needed to facilitate delivery to the stomach and permit adequate absorption (see SPC)
Alendronate (Alendronic acid) 70mg/100ml Oral Solution will be considered GREEN on the traffic light system